ArticleJournal of obesity2010
Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents.
Article in Journal of obesity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Efficacy of pharmacotherapies on pediatric patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis.BMC gastroenterology · 2025Pooled it
- The effects of metformin on simple obesity: a meta-analysis.Endocrine · 2018Pooled it
- Pooled it
- Effects of multidisciplinary therapy on energy balance, inflammation, and metabolic diseases in adolescents with obesity: A narrative review.Annals of the New York Academy of Sciences · 2024Review
- The effects of weight loss interventions on children and adolescents with non-alcoholic fatty liver disease: A systematic review and meta-analysis.Obesity science & practice · 2024Review
- Lifestyle and Pharmacological Interventions and Treatment Indications for the Management of Obesity in Children and Adolescents.Children (Basel, Switzerland) · 2023Review
- Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity.Children (Basel, Switzerland) · 2022Review
- Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?Pharmaceuticals (Basel, Switzerland) · 2018Review
- Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).Molecular pharmaceutics · 2015Article
- Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.World journal of gastroenterology · 2014Review
- Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling pathway.Oxidative medicine and cellular longevity · 2014Article
- Metformin: an old but still the best treatment for type 2 diabetes.Diabetology & metabolic syndrome · 2013Article
- Lipotoxicity: effects of dietary saturated and transfatty acids.Mediators of inflammation · 2013Article
- Hepatic steatosis and Type 2 diabetes: current and future treatment considerations.Expert review of cardiovascular therapy · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective. To assess the long-term effects of metformin in combination with lifestyle intervention and its association between insulin levels and the degree of steatosis at ultrasonography (US) in obese adolescents. Methods. Thirty-five postpubertal obese boys were randomized into two groups: one receiving metformin in combination with a multidisciplinary lifestyle intervention versus a placebo group, which also received the same intervention. The visceral, subcutaneous fat and degree of steatosis were measured by ultrasonography. Fasting blood samples were collected to analyze glucose, insulin, insulin resistance, and aminotransferases. Repeated ANOVA measures were used to compare changes over time and between groups, and Spearman's correlations were used to identify an association between insulin and the degree of steatosis at US. Results. There was a positive correlation between the degree of steatosis at US with insulin concentrations and HOMA-IR. Long-term therapy plus metformin significantly reduced body weight, body mass index, insulin, HOMA-IR, and visceral fat. Conclusions. Metformin was more effective than the placebo in improving clinical parameters associated with obesity and steatosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.